Zydus Lifesciences gets USFDA nod for generic ascorbic acid injection

Zydus Lifesciences secured final USFDA approval for its generic ascorbic acid injection. This approval is for the treatment of scurvy in specific patient groups. The company's product is the generic equivalent of the Ascor injection. The USFDA designated this application as a Competitive Generic Therapy. Zydus will market the product in the United States market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/m7sBK6b
via IFTTT